Metabolic improvement with short‐term glucagon like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double‐blind placebo‐controlled trial

2021 ◽  
Author(s):  
Annemie Stege Bojer ◽  
Martin Heyn Sørensen ◽  
Jenny Bjerre ◽  
Peter Gæde ◽  
Niels Vejlstrup ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diastolic Dysfunction ◽  
Receptor Agonist ◽  
Controlled Trial ◽  
Short Term ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia ◽  
2016 ◽  
Vol 59 (7) ◽  
pp. 1412-1421 ◽  
Author(s):  
Lennart Tonneijck ◽  
Mark M. Smits ◽  
Marcel H. A. Muskiet ◽  
Trynke Hoekstra ◽  
Mark H. H. Kramer ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Controlled Trial ◽  
Double Blind ◽  
Renal Effects ◽  
Double Blind Placebo ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document